Molecular and Cellular Biochemistry

, Volume 462, Issue 1–2, pp 25–31 | Cite as

A novel compound, ferulic acid-bound resveratrol, induces the tumor suppressor gene p15 and inhibits the three-dimensional proliferation of colorectal cancer cells

  • Yuuga Sawata
  • Taiji Matsukawa
  • Satoshi Doi
  • Toshiyuki Tsunoda
  • Nagisa Arikawa
  • Natsumi Matsunaga
  • Koichiro Ohnuki
  • Senji Shirasawa
  • Yojiro KotakeEmail author


Resveratrol, a phytoalexin present in grapes and other edible foods, has been reported to have beneficial effects against various diseases including cancer. We previously reported that resveratrol and its derivative, caffeic acid-adducted resveratrol, selectively inhibit the three-dimensional (3D) proliferation of a human colorectal cancer cell line, HCT116 with activating KRAS mutation. Herein, we demonstrated that a novel compound, ferulic acid-bound resveratrol, also represses the 3D proliferation of HCT116 cells. We observed that resveratrol conjugated to two ferulic acids represses the 3D proliferation of HCT116 cells more strongly than resveratrol and resveratrol conjugated to one ferulic acid. Resveratrol conjugated to two ferulic acids also inhibited the 3D proliferation of MCF7 human breast cancer cells. We further uncovered that the resveratrol derivative increases the mRNA level of the tumor suppressor p15, a CDK inhibitor that functions as a brake of cell proliferation in HCT116 cells. These results imply that the resveratrol derivative represses 3D proliferation via increasing p15 expression in HCT116 cells.


Resveratrol derivative Three-dimensional proliferation CDK inhibitor p15 Colorectal cancer 



We thank Keishi Tamura and Haruna Okamoto for their helpful discussions and technical assistance. This work was supported by JSPS KAKENHI Grant Number 17K07184 (to YK) and the Naito Foundation (to YK). We thank Joe Barber Jr., PhD, from Edanz Group ( for editing a draft of this manuscript.

Compliance with ethical standards

Conflict of interest

The resveratrol derivatives (UHA023, UHA024, and UHA025) used in this study were provided by UHA Mikakuto Co., Ltd. Taiji Matsukawa and Satoshi Doi are employees of UHA Mikakuto Co., Ltd. The authors have no conflict of interest to declare.


  1. 1.
    O’Brien LE, Zegers MM, Mostov KE (2002) Building epithelial architecture: insights from three-dimensional culture models. Nat Rev Mol Cell Biol 3:531–537. PubMedCrossRefGoogle Scholar
  2. 2.
    Griffith LG, Swartz MA (2006) Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 7:211–224. PubMedCrossRefGoogle Scholar
  3. 3.
    Tsunoda T, Takashima Y, Fujimoto T, Koyanagi M, Yoshida Y, Doi K, Tanaka Y, Kuroki M, Sasazuki T, Shirasawa S (2010) Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. Neoplasia 12(5):397–404PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Mukherjee S, Dudley JI, Das DK (2010) Dose-dependency of resveratrol in providing health benefits. Dose Response 8:478–500PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Signorelli P, Ghidoni R (2005) Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 16:449–466. PubMedCrossRefGoogle Scholar
  6. 6.
    Carrizzo A, Forte M, Damato A, Trimarco V, Salzano F, Bartolo M, Maciag A, Puca AA, Vecchione C (2013) Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol 61:215–226. PubMedCrossRefGoogle Scholar
  7. 7.
    Tsunoda T, Ishikura S, Doi K, Matsuzaki H, Iwaihara Y, Shirasawa S (2014) Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture. Anticancer Res 34(8):4551–4555PubMedGoogle Scholar
  8. 8.
    Tsunoda T, Ishikura S, Doi K, Iwaihara Y, Hidesima H, Luo H, Hirose Y, Shirasawa S (2015) Establishment of a three-dimensional floating cell culture system for screening drugs targeting KRAS-mediated signaling molecules. Anticancer Res 35(8):4453–4459PubMedGoogle Scholar
  9. 9.
    Okamoto H, Matsukawa T, Doi S, Tsunoda T, Sawata Y, Naemura M, Ohnuki K, Shirasawa S, Kotake Y (2018) A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation. Mol Cell Biochem 442(1–2):39–45PubMedCrossRefGoogle Scholar
  10. 10.
    Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512PubMedCrossRefGoogle Scholar
  11. 11.
    Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677PubMedCrossRefGoogle Scholar
  12. 12.
    Shirasawa S, Furuse M, Yokoyama N, Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85–88PubMedCrossRefGoogle Scholar
  13. 13.
    Doi S, Kishi A, Matsukawa T, Nojima M, Matsui T, Yamada Y, Yamada I (2015) A novel resveratrol derivative. Japan. Patent 5703887Google Scholar
  14. 14.
    Kishi A, Matsukawa T, Doi S, Nojima M, Matsui T, Yamada Y, Yamada I (2015) A novel resveratrol derivative. Japan. Patent 5673091Google Scholar
  15. 15.
    Doi S, Matsukawa T, Kishi A, Nojima M, Matsui T, Yamada Y, Yamada I (2015) A novel resveratrol derivative. Japan. Patent 5728972Google Scholar
  16. 16.
    Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y (2007) pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 21:49–54. PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Kotake Y, Goto T, Naemura M, Inoue Y, Okamoto H, Tahara K (2017) Long noncoding RNA PANDA positively regulates proliferation of osteosarcoma cells. Anticancer Res 37:81–85. PubMedCrossRefGoogle Scholar
  18. 18.
    Janicke B, Hegardt C, Krogh M, Onning G, Akesson B, Cirenajwis HM, Oredsson SM (2011) The antiproliferative effect of dietary fiber phenolic compounds ferulic acid and p-coumaric acid on the cell cycle of Caco-2 cells. Nutr Cancer 63:611–622. CrossRefGoogle Scholar
  19. 19.
    Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257–261. PubMedCrossRefGoogle Scholar
  20. 20.
    Rich JN, Zhang M, Datto MB, Bigner DD, Wang XF (1999) Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem 274:35053–35058PubMedCrossRefGoogle Scholar
  21. 21.
    Feng XH, Lin X, Derynck R (2000) Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J 19:5178–5193. PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, Xiong Y (2011) Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 30:1956–1962. PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Yuuga Sawata
    • 1
  • Taiji Matsukawa
    • 3
  • Satoshi Doi
    • 3
  • Toshiyuki Tsunoda
    • 4
    • 5
  • Nagisa Arikawa
    • 1
  • Natsumi Matsunaga
    • 1
  • Koichiro Ohnuki
    • 1
    • 2
  • Senji Shirasawa
    • 4
    • 5
  • Yojiro Kotake
    • 1
    • 2
    Email author
  1. 1.Graduate School of Humanity-Oriented Science and EngineeringKindai UniversityIizukaJapan
  2. 2.Department of Biological and Environmental Chemistry, Faculty of Humanity-Oriented Science and EngineeringKindai UniversityIizukaJapan
  3. 3.Technology Development SectionUHA Mikakuto Co., LtdOsakaJapan
  4. 4.Department of Cell Biology, Faculty of MedicineFukuoka UniversityFukuokaJapan
  5. 5.Central Research Institute for Advanced Molecular Medicine, Fukuoka UniversityFukuokaJapan

Personalised recommendations